Tetraphase Pharmaceuticals, Inc.

Stock Exchange: XNAS Ticker: TTPH HQ: Watertown, MA, USA Employees: 66 Signatory to Davos Decl: Yes Signatory to Industry Roadmap: No
Performance by research area
How Tetraphase Pharmaceuticals, Inc. was evaluated
1 2.1 2.2 2.3 3 4
R&D A
1 2 3
M&P B
1 2 3 4 5 6 7
AA&S C
Applicable indicator Not applicable

Performance

Tetraphase is a biopharmaceutical company, selected for having a pipeline that targets priority pathogens. It was evaluated in the area of Research & Development only. It invested USD 64 million in antibiotic drug development in 2016, which is high compared to other biopharmaceutical companies in the Benchmark. The company performs well compared with other biopharmaceutical companies in scope. It has three projects in its antimicrobial R&D pipeline, all targeting priority pathogens. Tetraphase engages in public-private partnerships to develop its antibiotic candidates. The company has one antibiotic in late-stage clinical development. Tetraphase is the only biopharmaceutical company identified by the Benchmark to have both an access and stewardship provision in place for an antibiotic in late-stage clinical development.

Operations

Tetraphase, founded in 2006, is a biopharmaceutical company focusing on the design and development of fully synthetic tetracycline antibiotics targeting multidrug-resistant bacteria. The company’s proprietary chemistry platform has resulted in a library of tetracycline analogues containing more than 2,500 compounds. The company’s most advanced drug candidate, eravacycline, is a broad-spectrum antibiotic being developed in both oral and intravenous formulations for the treatment of resistant and multidrug-resistant infections. The compound is currently undergoing Phase III trials for the treatment of complicated intra-abdominal infections and complicated urinary tract infections. Tetraphase has no products on the market. In recent years, Tetraphase has secured several grants from various partners, including the US National Institute of Allergy and Infectious Diseases (NIAID) and BARDA. The latter currently supports the joint development of eravacycline with the R&D company CUBRC. In 2017, Tetraphase was awarded USD 4 million (over an 18-month period) by CARB-X, to further develop TP6076, an investigational synthetic fluorocycline antibiotic that targets multidrug-resistant gram-negative bacteria. The company is also exploring the use of its tetracycline candidate compounds in other therapeutic areas, including oncology and inflammatory diseases. In 2013, Tetraphase was listed on the NASDAQ stock exchange, where it raised USD 75 million.

Antimicrobial Portfolio

Tetraphase does not have any products on the market.

Opportunities

Expand stewardship provisions for eravacycline. Tetraphase is the only company to have access and stewardship provisions (involving a surveillance programme), for an antibiotic in late-stage clinical development. It can ensure that further stewardship provisions are in place, e.g., appropriate promotion practices.

A. Research & Development

Indicators scored on
  • 1
  • 2.1
  • 2.2
  • 2.3
  • 3
  • 4
Antimicrobial pipeline
3 projects, 3 target priority pathogens

A.2.1-2.2 Pipeline focussed on tetracycline antibiotics. 

Biopharmaceutical companies in scope were selected based on their pipelines that target priority bacteria. Tetraphase invested USD 64 million in antimicrobial R&D in 2016. The company has three projects in its antimicrobial R&D pipeline targeting priority pathogens, all of which are broad-spectrum fluorocycline candidates. Its leading candidate is eravacycline, a broad-spectrum antibiotic in development for complicated intra-abdominal infections and complicated urinary tract infections. Its two other tetracycline compounds (TP271 and TP6076) are in Phase I clinical development for the treatment of gram-negative bacterial infections.

A.3 All R&D projects being developed with public partners. 

Tetraphase is developing all three R&D projects in its priority pathogen pipeline through public-private partnership (including a non-profit organisation). Tetraphase has received funding from BARDA for the development of eravacycline, NIAID for TP271 and CARB-X for TP6076. Through CARB-X, Tetraphase also shares IP rights with the Wellcome Trust for TP6076. This enables the Wellcome Trust to commercialise the medicine in underserved markets, if necessary.

A.4 Only biopharmaceutical company to have both an access and stewardship provision in place. 

Tetraphase reports that it has both an access and stewardship provision in place for its antibiotic in late-stage development. It is the only biopharmaceutical company to have these provisions in place for an investigational antibiotic (eravacycline). Following approval, the company intends to commercialise eravacycline directly in the USA and the EU. The company is actively seeking partners to develop and commercialise eravacycline in regions including Asia-Pacific, Eastern Europe, India, Middle East, North Africa and South America. For this indicator, countries in scope are 106 low- and middle-income countries where access to medicine is likely limited. Tetraphase has an ongoing global surveillance programme in collaboration with IHMA, Inc., which monitors the susceptibility to eravacycline of gram-negative and gram-positive bacteria and anaerobes in all types of hospitals (government, teaching, community, etc.). 1.5 full-time equivalent employees (FTEs) are dedicated to the surveillance programme and its Antimicrobial Voluntary Evaluation Program (AVEP). AVEP provides strips and disks that enable hospitals to test susceptibility of pathogens to the antibiotic. The annual cost of the global surveillance programme is USD 750,000, and the annual cost of AVEP is USD 350,000 (for US and EU markets).

Pipeline targeting priority pathogens

Enlarge

B. Manufacturing & Production

As a biopharmaceutical company with no products on the market, Tetraphase was not eligible for this Research Area.

C. Appropriate Access & Stewardship

As a biopharmaceutical company with no products on the market, Tetraphase was not eligible for this Research Area.

Animal Health & Diagnostics

Activities in this area are not scored by the Benchmark. This information is provided given the importance of animal health and diagnostics on the topic of AMR.

Tetraphase supports the Antimicrobial Voluntary Evaluation Program (AVEP), which provides strips and disks that enable hospitals to test the susceptibility of pathogens to its antibiotic candidate eravacycline.



Got a question?

Learn more

View our detailed overview of each company’s performance